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HYPOTHESIS

RESULTS

Synthetic inhibitors of B7-H3 will demonstrate an anti-neoplastic
response in Group 3 medulloblastoma.

B7-H3-Ni1 treatment demonstrates anti-neoplastic properties.

ABSTRACT
Medulloblastomas (MB) are devastating brain tumors originating in the cerebellum most
commonly in children. There are four distinct subgroups of medulloblastoma: WNT (wingless),
SHH (sonic hedgehog), group 3, and group 4. The most malignant tumors possess an aggressive
phenotype characterized by c-Myc amplification and deletions to chromosome 17p; they
belong to group 3. Prior investigations into the significance of genes on 17p revealed that miR1253, which is found on locus 17p13.3, is significantly downregulated in medulloblastoma and
has important tumor suppressive properties. Amongst its oncogenic targets is B7-H3 (CD276),
a highly deregulated oncoprotein that attenuates the immune response to MB tumors. We
chose to elucidate the oncogenic properties of B7-H3 in group 3 MB using synthetic inhibitors.
After screening 100,000 different compounds for: 1) docking ability, 2) oral bioavailability, 3)
potential CNS activity, and 4) number of metabolic side reactions, we selected two N-terminal
inhibitors: B7-H3-Ni1 and B7-H3-Ni3. In HDMB03 cells (with c-Myc amplification and i17q),
we found an IC50 of 3.7 𝛍M for B7-H3-Ni1 and no discernible effect of B7-H3-Ni3. We confirmed
CD276 expression inhibition using B7-H3-Ni1 via Western blotting and concurrently noted
elevations in cleaved PARP (apoptosis) and reduction in p-Akt (proliferation marker),
providing us preliminary insights into the mechanism of inhibition. Notably, a remarkable
decline in migration and wound healing and abrogation of colony formation were observed
with B7-H3-Ni1. Collectively, our findings substantiate the inhibitory properties of B7-H3-Ni1
in vitro, potentially serving as a therapeutic agent for in vivo group 3 MB tumors.
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RESULTS
B7-H3 is deregulated in Group 3 medulloblastoma.
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Figure 5. Effect of B7-H3-Ni1 on colony
formation, trans-well migration, and
wound healing. The functional assays
demonstrated a significant reduction in (A)
colony formation,
(B) trans-well
migration, and (C) wound healing
(monitored up to 72h) with the presence of
B7-H3-Ni1. Statistical analysis was
performed via Student’s t-test. *p <0.05,
**p <0.005, and ***p <0.001. Scale bar: 100
µM.
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CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions

BACKGROUND
v Group 3 medulloblastomas are one of the most aggressive malignant pediatric tumors of
the central nervous system. They express frequent c-Myc amplification and i17q.1,2
v Our prior studies have revealed that miR-1253, found on the terminal end of chromosome
17, is epigenetically silenced and has important tumor suppressive properties.1
v Two identified oncogenic targets of miR-1253 include CDK6 and CD276 (B7-H3).1
Ø B7-H3 is deregulated in group 3 tumors of MB patients.
v B7-H3 is a transmembrane immune checkpoint protein that is overexpressed in
medulloblastoma. It inhibits tumor infiltration by T cells and promotes metastasis.3
v Previous clinical investigations have demonstrated promising results in targeting B7-H3
with conjugated monoclonal antibodies (mAbs).4
v Other methods of targeting B7-H3, including the use of small-molecule inhibitors and
chimeric antigen receptor T cells, are currently being investigated.4
Ø An inhibitor binding to B7-H3 blocks the interaction between the receptor on the
immune cell and the ligand on the tumor cell, recovering immune cell function.5
v Expression patterns of B7-H3 across different malignancies, especially in pediatric brain
tumors, makes it an important target for cancer therapy.5

METHODOLOGY
Establish that
B7-H3 is highly
upregulated in
Group 3
medulloblastoma.

(Figure 1)

Select top
inhibitors based
on established
criteria.
(Figure 2)

Determine IC50
of selected
inhibitors with
MTT assay.
(Figure 3)

Figure 1. Differential expression of B7-H3 in medulloblastoma. (A) In silico analysis showing the expression of B7-H3 across MB datasets (R2 platform;
NC=normal cerebellum; MB=medulloblastoma). (B) Kaplan Meier curve showing MB patient survival (Cavali et al.). Subgroup specific expression of B7-H3 in
patient samples (C) GSE124814 and (D) GSE148390. (E) Immunohistochemical analysis of B7-H3 in MB patient samples (pedi CB n = 10, adult CB n = 5, SHH n =
3, Grp3 n = 6, Grp4 n = 10). (F) B7-H3 expression across three MB cell lines compared to normal human astrocytes. Statistical analysis performed via MannWhitney U test (D), ANOVA (A and C), and Student’s t-test (E). *p <0.05, **p <0.01, ***p <0.001. β-Actin served as an internal loading control. Scale bar:100µm.

Evaluation of synthetic inhibitors of B7-H3.
N-terminal site blockers
Inhibitor Docking score #metab %OralAbs CNS score
B7-H3-Ni1
-9.381
6
81.038
1
B7-H3-Ni2
-9.094
3
100.000
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B7-H3-Ni3
-8.694
3
100.000
1
C-terminal site blockers
Inhibitor Docking score #metab %OralAbs CNS score
B7-H3-Ci1
-6.158
7
100.00
1
B7-H3-Ci2
-5.538
3
74.302
-2

Figure 2. Analysis and selection of potential inhibitors of B7-H3. 100,000 synthetic compounds were analyzed using the crystal structure of human B7-H3,
which was modelled through the YASARA structure program. The docking ability of these molecules on either the N- or C- terminus of B7-H3 was evaluated.
From a total of top 113 hits, two inhibitors were selected for further investigation based on established criteria.

Analyze colony
formation,
migration, and
wound healing.
(Figure 5)

Future Directions

v Re-capitulate inhibitory effects in additional medulloblastoma cell lines, such as D341 and
D425.
v Assess impact on expression of downstream effectors of B7-H3, such as NF-κB, PI3K, HIF1α, and STAT3.6
v Further explore colonogenic inhibition by inhibitor via medullosphere assay and assess
stem cell markers.
v Conduct co-culturing experiments of medulloblastoma cell lines with immune cells (T-cells)
in the presence of B7-H3-Ni1.
v Perform in vivo orthotopic experiments to assess the therapeutic potential of B7-H3-Ni1 on
tumor growth and survival.

B7-H3-Ni1 effectively reduces cell proliferation in HDMB03 cells.
A

B

IC50

Evaluate B7-H3
expression,
apoptotic/
proliferation
markers.
(Figure 4)

v B7-H3-Ni1 effectively attenuated CD276 expression and favored apoptosis.
v B7-H3-Ni1 exhibited anti-tumorigenic properties by reducing colony formation, migration,
and wound healing.

B7-H3-Ni1

B7-H3-Ni3

3.7 µM

0.002 M

B7-H3-Ni1
IC50

24h

48h

72h

92h

4.6 µM

5.1 µM

3.7 µM

3.2 µM

Figure 3. Cell inhibition in response to
drug treatment for HDMB03 cell line
measured by the MTT assay. (A) IC50
values were determined following 48h
treatment with 0.05, 0.1, 0.25, 0.5, 0.75, 1,
2.5, and 5 uM concentration of B7-H3-Ni1
and B7-H3-Ni3. (B) IC50 values following
treatment with 1, 2, 3, 3.5, 4, 5, 6, 7, and 8
uM concentration of inhibitor B7-H3-Ni1
with 24, 48, 72, and 96h incubation
periods.

B7-H3-Ni1 decreases B7-H3 expression and favors apoptosis.
cl-PARP:PARP

VC

B7-H3-Ni1

0.093

0.367

Figure 4. Analysis of expression of B7-H3 and
apoptotic/tumor cell proliferation markers. A
significant decrease in expression of B7-H3 was observed
at the translational level with B7-H3-Ni1 treatment.
Elevations in an apoptotic marker (cleaved-PARP) and
reduction in a tumor proliferation marker (p-AKT) were
also noted. The ratio of cleaved PARP to total PARP is
tabulated. β-Actin served as an internal loading control.
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